Vertex Pharmaceuticals Incorporated Peer Comparison

Metric Value Ranking
Market Cap $121.2 Billion 1/21 VRTX
$121.2B		 REGN
$112.8B		 SGEN
$43.2B		 ALNY
$34.9B		 BNTX
$28.3B		 MRNA
$24.3B		 BMRN
$13.3B		 SRPT
$11.7B		 VKTX
$7.2B		 RETA
$6.6B		 KRYS
$5.1B		 MDGL
$4.5B		 CRSP
$3.9B		 PTCT
$2.8B		 BEAM
$1.9B		 NTLA
$1.9B		 ICPT
$794.7M		 DNA
$428.5M		 VERV
$406.2M		 EDIT
$265.6M		 CRBU
$160.8M
Gross Margin 86% 8/21 ICPT
100%		 BEAM
100%		 RETA
96%		 MDGL
96%		 ALNY
90%		 PTCT
90%		 KRYS
89%		 VRTX
86%		 SRPT
85%		 REGN
83%		 BMRN
80%		 SGEN
75%		 CRBU
75%		 VERV
75%		 NTLA
63%		 BNTX
54%		 DNA
45%		 MRNA
35%		 VKTX
0%		 EDIT
-100%		 CRSP
-100%
Profit Margin -100% 11/21 RETA
100%		 REGN
40%		 KRYS
22%		 BMRN
15%		 SRPT
2%		 VKTX
0%		 ALNY
-3%		 ICPT
-3%		 SGEN
-33%		 PTCT
-53%		 VRTX
-100%		 MDGL
-100%		 EDIT
-100%		 NTLA
-100%		 CRSP
-100%		 MRNA
-100%		 BEAM
-100%		 BNTX
-100%		 CRBU
-100%		 VERV
-100%		 DNA
-100%
EBITDA margin -132% 10/21 REGN
34%		 KRYS
33%		 BMRN
18%		 ALNY
10%		 SRPT
3%		 ICPT
-3%		 PTCT
-14%		 SGEN
-34%		 VKTX
-100%		 VRTX
-132%		 DNA
-237%		 RETA
-356%		 BNTX
-505%		 MRNA
-549%		 VERV
-854%		 BEAM
-891%		 MDGL
-1110%		 CRBU
-1231%		 NTLA
-1961%		 EDIT
-13739%		 CRSP
-28320%
Quarterly Revenue $2.6 Billion 2/21 REGN
$3.5B		 VRTX
$2.6B		 BMRN
$708.7M		 ALNY
$659.8M		 SGEN
$648.7M		 SRPT
$362.9M		 MRNA
$241.0M		 PTCT
$186.7M		 BNTX
$142.1M		 ICPT
$88.8M		 KRYS
$70.3M		 DNA
$56.2M		 RETA
$22.7M		 MDGL
$14.6M		 BEAM
$11.8M		 NTLA
$7.0M		 VERV
$6.7M		 CRBU
$3.5M		 CRSP
$517,000		 EDIT
$513,000		 VKTX
$0
Quarterly Earnings -$3.6 Billion 21/21 REGN
$1.4B 		RETA
$193.0M 		BMRN
$107.2M 		KRYS
$15.6M 		SRPT
$6.5M 		ICPT
-$2.8M 		ALNY
-$16.9M 		VKTX
-$22.3M 		CRBU
-$37.7M 		VERV
-$49.8M 		EDIT
-$67.6M 		BEAM
-$91.1M 		PTCT
-$99.2M 		CRSP
-$126.4M 		NTLA
-$147.0M 		MDGL
-$152.0M 		SGEN
-$215.8M 		DNA
-$217.2M 		BNTX
-$892.2M 		MRNA
-$1.3B 		VRTX
-$3.6B
Quarterly Free Cash Flow -$3.8 Billion 21/21 BNTX
$1.6B 		REGN
$143.1M 		ALNY
$116.1M 		BMRN
$96.9M 		ICPT
$3.9M 		MDGL
-$0 		BEAM
-$0 		KRYS
-$5.3M 		SRPT
-$14.2M 		VKTX
-$28.5M 		CRBU
-$35.1M 		VERV
-$35.1M 		NTLA
-$59.2M 		EDIT
-$60.6M 		PTCT
-$64.1M 		RETA
-$70.2M 		SGEN
-$79.8M 		CRSP
-$96.3M 		DNA
-$111.4M 		MRNA
-$1.5B 		VRTX
-$3.8B
Trailing 4 Quarters Revenue $10.3 Billion 3/21 BMRN
$648.1B		 REGN
$13.5B		 VRTX
$10.3B		 MRNA
$5.1B		 BNTX
$3.0B		 ALNY
$2.3B		 SGEN
$2.3B		 SRPT
$1.5B		 PTCT
$900.5M		 BEAM
$352.6M		 ICPT
$317.7M		 CRSP
$201.0M		 DNA
$184.3M		 KRYS
$157.7M		 EDIT
$61.7M		 NTLA
$46.0M		 CRBU
$33.1M		 RETA
$24.4M		 VERV
$20.6M		 MDGL
$14.6M		 VKTX
$0
Trailing 4 Quarters Earnings -$489.9 Million 15/21 REGN
$3.5B 		VRTX
$2.6B 		BMRN
$708.7M 		ALNY
$659.8M 		SGEN
$648.7M 		SRPT
$362.9M 		MRNA
$241.0M 		PTCT
$186.7M 		BNTX
$142.1M 		ICPT
$88.8M 		KRYS
$70.3M 		DNA
$56.2M 		RETA
$22.7M 		MDGL
$14.6M 		BEAM
$11.8M 		NTLA
$7.0M 		VERV
$6.7M 		CRBU
$3.5M 		CRSP
$517,000 		EDIT
$513,000 		VKTX
-$0
Quarterly Earnings Growth -492% 21/21 RETA
362% 		KRYS
137% 		SRPT
127% 		ALNY
94% 		PTCT
50% 		REGN
48% 		VERV
8% 		MRNA
7% 		BEAM
-10% 		SGEN
-13% 		VKTX
-16% 		NTLA
-19% 		DNA
-25% 		CRBU
-28% 		CRSP
-63% 		EDIT
-68% 		MDGL
-77% 		BMRN
-100% 		ICPT
-101% 		BNTX
-326% 		VRTX
-492%
Annual Earnings Growth -116% 18/21 SRPT
103% 		KRYS
94% 		ALNY
91% 		RETA
72% 		BEAM
57% 		REGN
26% 		PTCT
22% 		VERV
-1% 		EDIT
-9% 		CRSP
-12% 		DNA
-14% 		CRBU
-18% 		SGEN
-26% 		NTLA
-27% 		VKTX
-29% 		MDGL
-60% 		BMRN
-63% 		VRTX
-116% 		ICPT
-124% 		BNTX
-139% 		MRNA
-413%
Quarterly Revenue Growth 6% 8/21 RETA
2885% 		VERV
220% 		ALNY
107% 		SRPT
39% 		SGEN
27% 		ICPT
14% 		REGN
12% 		VRTX
6% 		VKTX
0% 		MDGL
0% 		KRYS
0% 		CRBU
-8% 		PTCT
-13% 		BNTX
-23% 		MRNA
-30% 		DNA
-30% 		BEAM
-41% 		NTLA
-49% 		EDIT
-82% 		CRSP
-99% 		BMRN
-100%
Annual Revenue Growth 7% 11/21 RETA
596% 		BEAM
280% 		VERV
227% 		CRBU
132% 		EDIT
90% 		ALNY
84% 		SRPT
47% 		SGEN
15% 		BMRN
9% 		ICPT
8% 		VRTX
7% 		REGN
7% 		PTCT
3% 		VKTX
0% 		MDGL
0% 		KRYS
0% 		NTLA
-11% 		MRNA
-15% 		BNTX
-33% 		DNA
-43% 		CRSP
-46%
Cash On Hand $4.6 Billion 2/21 BNTX
$11.4B 		VRTX
$4.6B 		MRNA
$2.5B 		REGN
$1.9B 		BMRN
$972.2M 		ALNY
$968.5M 		DNA
$732.7M 		PTCT
$654.8M 		MDGL
$494.6M 		CRSP
$484.5M 		SGEN
$428.6M 		SRPT
$383.6M 		KRYS
$345.8M 		BEAM
$292.8M 		VERV
$141.5M 		NTLA
$130.8M 		ICPT
$102.7M 		EDIT
$64.4M 		RETA
$48.8M 		VKTX
$43.9M 		CRBU
$37.9M
Short Term Debt $0 17/21 BMRN
$505.5M 		ALNY
$103.6M 		SRPT
$91.5M 		BNTX
$38.8M 		MRNA
$25.0M 		NTLA
$19.0M 		EDIT
$18.2M 		CRSP
$16.5M 		PTCT
$16.0M 		BEAM
$12.6M 		VERV
$10.3M 		RETA
$2.5M 		CRBU
$1.8M 		KRYS
$1.4M 		MDGL
$557,000 		VKTX
$334,000 		VRTX
-$0 		REGN
-$0 		SGEN
-$0 		ICPT
-$0 		DNA
-$0
Long Term Debt $933.4 Million 5/21 ALNY
$2.4B		 REGN
$2.0B		 MRNA
$1.2B		 SRPT
$1.1B		 VRTX
$933.4M		 BMRN
$594.1M		 DNA
$452.3M		 PTCT
$284.8M		 BNTX
$241.0M		 ICPT
$223.9M		 CRSP
$214.9M		 RETA
$163.5M		 BEAM
$152.6M		 SGEN
$113.5M		 NTLA
$87.3M		 VERV
$62.2M		 CRBU
$25.5M		 EDIT
$20.5M		 VKTX
$766,000		 MDGL
$0		 KRYS
$0
PE -1.00 4/21 SRPT
247.04		 REGN
26.10		 BMRN
0.64		 VRTX
-1.00		 ALNY
-1.00		 VKTX
-1.00		 RETA
-1.00		 SGEN
-1.00		 ICPT
-1.00		 MDGL
-1.00		 PTCT
-1.00		 EDIT
-1.00		 NTLA
-1.00		 CRSP
-1.00		 KRYS
-1.00		 MRNA
-1.00		 BEAM
-1.00		 BNTX
-1.00		 CRBU
-1.00		 VERV
-1.00		 DNA
-1.00
PS 11.75 9/21 MDGL
310.23		 RETA
269.17		 NTLA
40.99		 KRYS
32.32		 VERV
19.67		 CRSP
19.37		 SGEN
18.76		 ALNY
14.87		 VRTX
11.75		 BNTX
8.70		 REGN
8.36		 SRPT
7.76		 BEAM
5.49		 CRBU
4.86		 MRNA
4.81		 EDIT
4.30		 PTCT
3.11		 ICPT
2.50		 DNA
2.32		 BMRN
0.02		 VKTX
-1.00
PB 8.21 5/21 RETA
75.22		 SGEN
16.92		 ICPT
11.06		 SRPT
10.85		 VRTX
8.21		 VKTX
7.78		 KRYS
6.07		 MDGL
5.30		 REGN
4.00		 BMRN
2.51		 BEAM
2.27		 MRNA
2.07		 CRSP
1.97		 NTLA
1.94		 BNTX
1.35		 EDIT
1.14		 VERV
0.74		 CRBU
0.52		 DNA
0.51		 ALNY
0.00		 PTCT
0.00
PC 26.47 7/21 VKTX
163.21		 RETA
134.44		 SGEN
100.70		 REGN
58.49		 ALNY
36.00		 SRPT
30.46		 VRTX
26.47		 KRYS
14.74		 NTLA
14.40		 BMRN
13.64		 MRNA
9.80		 MDGL
9.18		 CRSP
8.04		 ICPT
7.74		 BEAM
6.62		 PTCT
4.28		 CRBU
4.25		 EDIT
4.12		 VERV
2.87		 BNTX
2.48		 DNA
0.58
Liabilities to Equity 0.36 8/21 RETA
4.76		 ICPT
4.47		 SRPT
2.18		 DNA
0.95		 EDIT
0.66		 BEAM
0.48		 SGEN
0.42		 VRTX
0.36		 BMRN
0.34		 MRNA
0.34		 REGN
0.28		 MDGL
0.28		 VERV
0.28		 NTLA
0.23		 CRBU
0.20		 CRSP
0.18		 BNTX
0.17		 KRYS
0.09		 VKTX
0.03		 ALNY
0.00		 PTCT
0.00
ROA -0.02 5/21 BMRN
292% 		REGN
12% 		SRPT
1% 		KRYS
-1% 		VRTX
-2% 		ALNY
-2% 		BNTX
-3% 		VKTX
-10% 		CRSP
-11% 		BEAM
-11% 		ICPT
-15% 		RETA
-16% 		SGEN
-21% 		PTCT
-25% 		VERV
-27% 		CRBU
-33% 		MRNA
-37% 		NTLA
-43% 		MDGL
-46% 		EDIT
-50% 		DNA
-55%
ROE -0.03 7/21 ALNY
2378% 		BMRN
390% 		PTCT
49% 		REGN
15% 		SRPT
4% 		KRYS
-1% 		VRTX
-3% 		BNTX
-3% 		VKTX
-11% 		CRSP
-13% 		BEAM
-17% 		SGEN
-29% 		VERV
-35% 		CRBU
-40% 		MRNA
-50% 		NTLA
-52% 		MDGL
-60% 		ICPT
-82% 		EDIT
-83% 		RETA
-94% 		DNA
-108%
Current Ratio 3.76 12/21 VKTX
36.62		 KRYS
11.65		 BNTX
7.02		 CRSP
6.52		 CRBU
5.97		 NTLA
5.40		 REGN
4.58		 MDGL
4.53		 VERV
4.53		 BMRN
3.97		 MRNA
3.95		 VRTX
3.76		 SGEN
3.35		 BEAM
3.10		 EDIT
2.52		 DNA
2.05		 SRPT
1.46		 ICPT
1.22		 RETA
1.21		 ALNY
1.00		 PTCT
0.66
Quick Ratio 1.08 14/21 SRPT
247.04		 REGN
26.10		 BMRN
0.64		 VRTX
-1.00		 ALNY
-1.00		 VKTX
-1.00		 RETA
-1.00		 SGEN
-1.00		 ICPT
-1.00		 MDGL
-1.00		 PTCT
-1.00		 EDIT
-1.00		 NTLA
-1.00		 CRSP
-1.00		 KRYS
-1.00		 MRNA
-1.00		 BEAM
-1.00		 BNTX
-1.00		 CRBU
-1.00		 VERV
-1.00		 DNA
-1.00
Long Term Debt to Equity 0.06 14/21 ICPT}
3.12		 RETA}
1.87		 SRPT}
1.05		 DNA}
0.54		 BEAM}
0.18		 BMRN}
0.11		 CRSP}
0.11		 MRNA}
0.11		 VERV}
0.11		 EDIT}
0.09		 NTLA}
0.09		 CRBU}
0.08		 REGN}
0.07		 VRTX}
0.06		 SGEN}
0.04		 BNTX}
0.01		 VKTX}
0.00		 MDGL}
0.00		 KRYS}
0.00		 PTCT}
-0.29		 ALNY}
-771.20
Debt to Equity 0.06 14/21 ICPT
3.12		 RETA
1.90		 SRPT
1.27		 DNA
0.54		 BMRN
0.21		 BEAM
0.19		 EDIT
0.17		 VERV
0.13		 CRSP
0.12		 NTLA
0.11		 MRNA
0.11		 REGN
0.10		 CRBU
0.09		 VRTX
0.06		 SGEN
0.04		 KRYS
0.01		 BNTX
0.01		 VKTX
0.00		 MDGL
0.00		 PTCT
-0.40		 ALNY
-883.03
Burn Rate 1.26 15/21 BMRN
22.62		 BNTX
11.41		 ICPT
8.75		 ALNY
7.05		 SRPT
6.21		 PTCT
5.71		 CRSP
3.48		 MDGL
3.25		 DNA
3.11		 BEAM
2.92		 VERV
2.58		 VKTX
1.96		 SGEN
1.95		 MRNA
1.86		 VRTX
1.26		 CRBU
0.97		 EDIT
0.88		 NTLA
0.84		 RETA
-0.26		 REGN
-1.43		 KRYS
-22.71
Cash to Cap 0.04 15/21 DNA
1.71		 BNTX
0.40		 VERV
0.35		 EDIT
0.24		 CRBU
0.24		 PTCT
0.23		 BEAM
0.15		 ICPT
0.13		 CRSP
0.12		 MDGL
0.11		 MRNA
0.10		 BMRN
0.07		 NTLA
0.07		 KRYS
0.07		 VRTX
0.04		 ALNY
0.03		 SRPT
0.03		 REGN
0.02		 VKTX
0.01		 RETA
0.01		 SGEN
0.01
CCR 1.07 3/21 VKTX
1.28		 MRNA
1.14		 VRTX
1.07		 CRBU
0.93		 BMRN
0.90		 EDIT
0.90		 CRSP
0.76		 VERV
0.71		 PTCT
0.65		 DNA
0.51		 NTLA
0.40		 SGEN
0.37		 REGN
0.10		 MDGL
0.00		 BEAM
0.00		 KRYS
-0.34		 RETA
-0.36		 ICPT
-1.38		 BNTX
-1.85		 SRPT
-2.20		 ALNY
-6.88
EV to EBITDA -33.88 17/21 SRPT}
1053.25		 ALNY}
575.34		 KRYS}
206.40		 BMRN}
103.06		 REGN}
93.53		 VKTX}
-1.00		 DNA}
-1.11		 EDIT}
-3.40		 CRBU}
-3.52		 VERV}
-5.90		 NTLA}
-13.63		 BEAM}
-17.25		 MRNA}
-17.45		 CRSP}
-24.86		 MDGL}
-24.90		 BNTX}
-32.10		 VRTX}
-33.88		 RETA}
-82.50		 PTCT}
-96.55		 SGEN}
-191.83		 ICPT}
-331.82
EV to Revenue 11.39 9/21 MDGL
276.48		 RETA
273.97		 NTLA
40.46		 KRYS
30.18		 SGEN
18.62		 CRSP
18.11		 VERV
16.33		 ALNY
15.61		 VRTX
11.39		 REGN
8.42		 SRPT
8.42		 BNTX
7.09		 BEAM
5.13		 MRNA
4.57		 CRBU
4.54		 EDIT
3.89		 ICPT
2.88		 PTCT
2.82		 DNA
0.80		 BMRN
0.02		 VKTX
-1.00

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions